AUTHORS
Laurence Pollissard, MS, Susanna Libby2, Kieran Wynne-Cattanach, MSc3, Katherine Smethers, MSci4, Maria Belen Rodriguez, MD5, Ahmed Daak, MD, PhD, MBA6
AFFILIATIONS
1 Sanofi, Gentilly, France
2 Adelphi Real World, Bollington, United Kingdom
3 Adelphi Real World, Bollington, United Kingdom
4 Adelphi Real World, Bollington, United Kingdom
5 Sanofi, Cambridge, Massachusetts, United States
6 Sanofi, Cambridge, Massachusetts, United States
ABSTRACT
Introduction: Warm autoimmune hemolytic anemia (wAIHA), the most prevalent subtype of AIHA, accounts for approximately 60–70% of cases. It is driven by complex immune dysregulation, characterized by the production of pathogenic IgG autoantibodies and systemic inflammation. Therapeutic options remain limited and no treatments are approved for wAIHA. This study evaluated treatment patterns and clinical burden in adults with primary wAIHA and collected patient-reported outcomes (PRO) to capture the patient perspective on symptoms, productivity, and quality of life.
Methods: Data were drawn from the Adelphi wAIHA Disease Specific Programme (DSP)™, a real-world cross-sectional survey with elements of retrospective data collection by physicians and patients in the United States (February–July 2025). Physicians were hematologists, hematologist-oncologists, or rheumatologists treating ≥5 wAIHA patients monthly. Eligible patients for this analysis, were adults (≥18 years) with a physician-confirmed primary wAIHA diagnosis, excluding secondary wAIHA and clinical trials participants. Outcomes included clinical characteristics, physician-assessed disease status, treatment patterns, healthcare resource utilization, PROs assessed using Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, Patient Global Impression of Fatigue Severity of Fatigue (PGI-S), and Work Productivity and Activity Impairment (WPAI) questionnaires. Fatigue severity was classified into four categories based on FACIT-Fatigue score thresholds: no fatigue (score 48–52), mild (40–47), moderate (29–39), and severe (0–28).
Results: Physicians (n=34) provided data for 243 primary wAIHA patients, of whom 64.2% were ≥45 years, 84.0% White, and median disease duration was 11.7 (inter quartile range: 4.7–16.2) months. Of these, PROs were completed by 55 patients. At survey, irrespective of treatment status, 61.3% had manifestations that had started to improve but persisted or had not improved, while 38.7% had significantly improved or resolved manifestations. Anemia was present in 81.4% of patients: 32.6% had mild anemia (10–11.9 g/dL), 40.5% had moderate anemia (8.0–9.9 g/dL) and 8.3% had severe anemia (<8.0 g/dL). Among 190 patients treated at survey, monoclonal antibodies and immunosuppressive treatments were most frequently prescribed (84.7%), with rituximab predominant (64.2%). Of the 52 corticosteroid (CS)-dependent patients (≥3 months systemic CS), 65.4% had persistent manifestations despite a mean (standard deviation [SD]) treatment duration of 306.0 (278.1) days. Thromboembolic (TE) events occurred in 17.7% patients (n=43) with deep vein thrombosis most common (53.5%), followed by transient ischemic attack (25.6%), cerebral ischemic attack (20.9%), myocardial infarction and pulmonary embolism (11.6% each), ischemic stroke (7.0%), and other venous thromboembolic events (4.7%). In the 12 months prior to survey, 33.7% of patients required blood transfusions, with 9.8% transfusion dependent. 21.5% were hospitalized with mean (SD) 3.1 (2.0) nights, 80.0% via emergency room, and 28.9% requiring blood transfusions, per the most recent hospitalization. Among 55 PRO respondents, 80.0% reported fatigue (FACIT-Fatigue score <48): 50.9% moderate-to-severe fatigue, 29.1% mild fatigue, while 20.0% reported no fatigue; mean (SD) score: 36.7 (11.2). PGI-S showed 60.0% mild fatigue, 25.5% moderate, 14.5% none; 0% severe. Agreement between physician-reported and patient-reported fatigue was fair when assessed by FACIT-Fatigue (k=0.394, p<0.001) and moderate when assessed by PGI-S (k=0.493, p<0.001). Of 52 patients reporting caregiver involvement, 23.1% received support (n=40), most commonly a husband, wife or partner (21.2%). Six patients reported mean (SD) duration of 4.0 (3.2) hours of caregiver support per week. Work productivity loss due to wAIHA (n=35) was 28.1% and daily activity impairment (n=55) was 26.4%. Additionally, 21.2% took sick days in the previous month with mean (SD) of 2.2 (1.3) days.
Conclusions: Despite treatments, most primary wAIHA patients experienced persistent manifestations and complications. TE events, blood transfusions, CS dependency, caregiver involvement and work impairment, demonstrate a substantial clinical and humanistic burden, further underscored by 80.0% of PRO completers reporting fatigue. Together, these findings highlight a significant unmet need for effective therapeutic options in wAIHA.
DISCLOSURES
Ahmed Daak, MD, PhD, MBA: Sanofi - Current holder of stock options in a privately-held company; Sanofi - Stock (publicly traded); Sanofi - Current Employment